

Results Presentation 1Q of FY Ending March 2026

WIN-Partners Co., Ltd. (3183)

1Q results to June 2025


Highlights

- Sales and profits increased YoY
- Sales in all major segments increased YoY
- Gross profit margins fell YoY due to narrowed product margins and sales mix changes
- Operating profit increased 20% YoY on the back of sales growth

Consolidated results summary

(¥ mil.) 1Q to	Jun. 2024	Jun. 2025	YoY (%)
Sales	19, 603	22,085	+12.7
Operating profit	586	701	+19.6
Recurring profit	587	708	+20.6
Net profit	396	480	+21. 2
EPS (yen)	13.89	16.98	_
BPS (yen)	782.80	792.56	_

Sales




- Sales in all major segments increased YoY
- Sales to new customers contributed
- Ablations (including pulse field ablation) expanded steadily

Sales breakdown by segment (YoY)

Comment	Sales	YoY growth (%)		% of sales
Segment	(¥ mil.)	Volume	Value	
Percutaneous coronary intervention (PCI)	4,993	+3.7	+8.5	22.6
Cardiac rhythm segment (CRS)	6,127	+15.0	+17.1	27.7
Cardiac vascular segment (CVS)	3,831	+3.6	+4.0	17.3
Percutaneous peripheral intervention (PPI)	1,200	-1.3	+3.5	5.4
Neurovascular	1,026	+7.6	+7.3	4.6
Non vascular	909	-	+3.6	4.1
Diabetes mellitus segment (DMS)	1,414	=	+35.8	6.4
Medical equipment	1,979	=	+47.3	9.0
Others	602	-	-14.2	2.7
Total	22,085	-	+12.7	100.0

Operating profit

YoY +19.6%



- Gross profit margin 11.7% (-0.4 pp YoY)
 - Product margins narrowed
 - Sales mix changed (sales of lower margin products increased)
- SGA +5.1% YoY
 - Labor costs: +3.5%
 - Other expenses: +9.3%
 - Number of employees: 638 (Jun. 2024) → 644 (Jun. 2025)

Initiatives for human capital

We have set following KPIs aiming to develop human resources supporting sustainable corporate activities and workplace environment where diverse human resources can thrive.

KPI	FY2024 Targets/Results	FY2025 Targets
Utilization rate of staggered working hours and flextime	Target: 70.0% Result: 67.4%	Target: 70.0%
Utilization rate of level-based education lessons and education tools for self-enlightenment	Target: 70.0% Result: 95.1%	Target: 80.0%
Maintain 25% female employment ratio	Target: 25.0% Result: 45.0%	Target: 30.0%
Percentage of promotion-to-manager recommendations for female employees	Target: 20.0% (3-year average) Result: 21.6% (3-year average)	Target: 20.0% (3-year average)
Percentage of male employees taking childcare leave	Target: 50.0% Result: 37.5%	Target: 50% (acquired rate) Target: 14 days (number of days taken)
Thorough education on compliance and human rights (Percentage of employees attending lectures)	Target: 100.0% Result: 100.0%	Target: 100.0%

References

Major products handled (1/2)

Segment	Product			
	Drug-eluting sten	t (DES) PTCA	balloon catheter	Intravascular ultrasound (IVUS) catheter
PCI	quand			The state of the s
	Watch the video he	r <u>e</u>		
	Pacemaker	Implantable cardioverter defibrillator (ICD)	Cardiac resynchronization therapy defibrillator (CRTD)	Ablation (ABL) catheter
CRS	Watch the video he	re		Watch the video here
	Stent graft	Transca	atheter aortic valve	Mechanical heart valve
CVS			Watch the video here	
	Peripheral vascula	ar stent		
PPI				

Major products handled (2/2)

Product Segment Ceurothrombectomy device Carotid stent Embolic coil Neuro vascular Watch the video here **Biopsy forceps** Self-expandable Colonic Stent Biliary Tube Stent System Non vascular Insulin pump Continuous Glucose Monitoring (CGM) **DMS** Design and construction Computed Tomography (CT) of operating room, etc. Medical equipment



Disclaimer

This material was prepared based on the information available and the views held at the time it was made. Statements in this material that are not historical facts, including but not limited to plans, forecasts and strategies are "forward-looking statements." Forward-looking statements are by their nature subject to various risks and uncertainties, including but not limited to a decline in general economic conditions, general market conditions, technological developments, changes in customer demand for products and services, increased competition, and other important factors, each of which may cause actual results and future developments to differ materially from those expressed or implied in any forward-looking statement.

With the passage of time, the information in this material (including but not limited to forward-looking statements) could be superseded or cease to be accurate. WIN-Partners Co., Ltd. disclaims any obligation or responsibility to update, revise, or supplement any forward-looking statement or other information in any material or generally to any extent. The utilization of or reliance on the information in this material is at your own risk.

Contact

WIN-Partners Co., Ltd. Investor Relations

Phone: +81-3-3548-0790

https://www.win-partners.co.jp/en/

Scan QR code for the homepage →

